2-甲氧基嘧啶-5-甲腈 | 38373-47-6

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-甲氧基嘧啶-5-甲腈
• 英文名称: 5-cyano-2-methoxypyrimidine
• 英文别名: 2-methoxypyrimidine-5-carbonitrile；2-methoxy-5-cyanopyrimidine；2-Methoxy-5-cyan-pyrimidin
• CAS: 38373-47-6
• 化学式: C₆H₅N₃O
• mdl: MFCD11840202
• 分子量: 135.125
• InChiKey: OZEMKEGUQJZPIV-UHFFFAOYSA-N

物化性质

• 沸点：
  292.2±32.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  58.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090
• 储存条件：
  存储条件：2-8°C，干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methoxypyrimidine-5-carbonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methoxypyrimidine-5-carbonitrile
CAS number: 38373-47-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5N3O
Molecular weight: 135.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲氧基嘧啶-5-甲腈 在 羟胺 作用下， 以 乙醇 、 水 为溶剂， 反应 16.0h， 生成 N-hydroxy-2-methoxypyrimidine-5-carboxamidine
  参考文献：
  名称：

  [EN] COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
  [FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES

  摘要：

  本发明涉及具有 GPR119 激动剂活性的治疗化合物，适用于治疗代谢性疾病，包括Ⅱ型糖尿病。

  公开号：

  WO2010103335A1
• 作为产物：
  描述：

  zinc(II) cyanide 、 5-溴-2-甲氧基嘧啶 在 四(三苯基膦)钯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-甲氧基嘧啶-5-甲腈
  参考文献：
  名称：

  [EN] COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
  [FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES

  摘要：

  本发明涉及具有 GPR119 激动剂活性的治疗化合物，适用于治疗代谢性疾病，包括Ⅱ型糖尿病。

  公开号：

  WO2010103335A1

文献信息

• Substrate Profiling of the Cobalt Nitrile Hydratase from Rhodococcus rhodochrous ATCC BAA 870
  作者：Adelaide R. Mashweu、Varsha P. Chhiba-Govindjee、Moira L. Bode、Dean Brady

  DOI：10.3390/molecules25010238

  日期：——

  cross-coupling reactions and imidazo[1,2-a]pyridines prepared by the Groebke–Blackburn–Bienaymé multicomponent reaction. The enzyme active site was moderately accommodating, accepting almost all of the small aromatic nitriles, the diarylpyridines and most of the bi-aryl compounds and Morita–Baylis–Hillman products but not the Groebke–Blackburn–Bienaymé products. Nitrile conversion was influenced by steric

  对来自玫瑰色红球菌 ATCC BAA 870 的钴腈水合酶的芳香底物特征进行了评估，并针对多种含腈化合物 (>60)。为了确定这种酶的底物限度，评估了大小从小 (90 Da) 到大 (325 Da) 的化合物。较大的化合物包括通过 Suzuki 偶联反应制备的具有双芳基轴的化合物、Morita-BAylis-Hillman 加合物、通过 Buchwald-Hartwig 交叉偶联反应制备的杂原子连接的二芳基吡啶和通过制备的咪唑并 [1,2-a] 吡啶Groebke-Blackburn-Bienaymé 多组分反应。酶活性位点适中，接受几乎所有的小芳香腈，二芳基吡啶和大多数双芳基化合物和 Morita-BAylis-Hillman 产品，但不是 Groebke-Blackburn-Bienaymé 产品。腈的转化率受氰基周围的空间位阻、芳环上给电子基团（例如甲氧基）的存在以及化合物的整体大小的影响。
• [EN] P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS DE P2X3 ET/OU P2X2/3 ET PROCÉDÉS
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2015095128A1

  公开（公告）日：2015-06-25

  The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

  本申请提供了新颖的化合物以及制备和使用这些化合物的方法。在一个实施例中，这些化合物具有如下式（I）的结构，其中R1-R4在此处被定义。在另一个实施例中，这些化合物在调节P2X3或P2X2/3受体中的一个或两个的方法中是有用的。在另一个实施例中，这些化合物通过向患者施用一个或多个化合物来治疗患者的疼痛是有用的。
• Improved Substrate Scope in the Potassium Hexacyanoferrate(II)-Based Cyanation for the Synthesis of Benzonitriles and Their Heterocyclic Analogues
  作者：Jeffery Richardson、Simon P. Mutton

  DOI：10.1021/acs.joc.8b00515

  日期：2018.5.4

  The use of Pd(DPEPhos)Cl2 (P26) as a catalyst for the formation of benzonitriles and their heterocyclic analogues provides excellent complementarity to existing catalysts, allowing highly electron-deficient heterocyclic aryl halides to be efficiently converted to the corresponding nitriles using K4[Fe(CN)6]) as cyanide source. This catalyst significantly enhances the scope of this reaction to include

  使用Pd（DPEPhos）Cl 2（P26）作为形成苄腈及其杂环类似物的催化剂可提供与现有催化剂的出色互补性，从而使高度缺电子的杂环芳基卤化物可通过K 4有效地转化为相应的腈[Fe（CN）6]）作为氰化物源。该催化剂大大增加了反应的范围，使其包含许多与制药和农业化学应用高度相关的底物。重要的是，这种氰化方法不仅使用无毒的氰化物源，简单的半定量测试表明，与许多其他方法不同，反应混合物中或在各种潜在的后处理过程中均不存在游离氰化物，从而提高了该方法的安全性。从初始设置到产品隔离。最终，开发和测试了一系列方便的氰化试剂盒，使得该方法易于应用，并在我们的实验室中得到了更广泛的采用。
• 一种2-氯-5-氰基嘧啶化合物制备方法
  申请人：都创（上海）医药科技有限公司

  公开号：CN110845426A

  公开（公告）日：2020-02-28

  本发明公开了一种2‑氯‑5‑氰基嘧啶化合物制备方法，该制备方法采用的路线是以氰基乙酸为原料，在N,N‑二甲基甲酰胺二甲基缩醛的作用下,以二氧六环为溶剂发生反应后生成3‑(二甲基氨)丙烯腈，然后依次经过维尔斯迈尔反应、加成反应、关环反应和氯化反应，最终得到成品2‑氯‑5‑氰基嘧啶化合物。本发明制备方法提供的合成路线原料廉价易得，后处理简单易纯化，每步反应无需柱层析纯化，本发明能够有效的克服现有技术文献中其它合成方法路线长、原料成本昂贵和需要柱层析等技术缺陷，本发明中提供的2‑氯‑5‑氰基嘧啶化合物制备方法对药物成本的降低具有重大的经济利益，本发明制备方法是一种成本低廉且适合工业化生产的技术。
• Compounds for the Treatment of Metabolic Disorders
  申请人：Barba Oscar

  公开号：US20120040953A1

  公开（公告）日：2012-02-16

  The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

  本发明涉及治疗化合物，其具有作为GPR119激动剂的活性，并且适用于治疗代谢性疾病，包括2型糖尿病。